Delirium is a condition of acute disturbance in attention and awareness along with disturbances in cognition. It is a symptom of deranged homeostasis and an early sign of infection or hypoxia. The occurrence of COVID-19 brought a catastrophic reduction in delirium monitoring, prevention, and patient care due to several organizational issues like lack of personnel, increased use of benzodiazepines and restricted family visitation.
For the future development of an ideal intensive care unit (ICU) it is important to make the patients free from delirium. As delirium is associated with worse ICU-related outcomes and long-term cognitive impairment in critical illnesses.
Screening for delirium requires limited time and effort. Completing good sedation practices by novel ICU design and connectivity will facilitate non-pharmacological sedation, anxiolysis and comfort which can further be supplemented by balanced pharmacological interventions when necessary. Improvements in the ICU sound, light control, floor planning, and room arrangement can also facilitate a healing environment which would eventually minimize stressors and aid delirium prevention and management.
The fundamental prerequisite to realize the delirium-free ICU, is an awake non-sedated, pain-free comfortable patient whose management follows the A to F (A–F) bundle. Moreover, gaining (G) insight into patient needs, delivering holistic care with a ‘home-like’ (H) environment, and redefining ICU architectural design (I).
The most important thing is to obtain a delirium-free world. It requires optimization of design of ICU, environmental factors, management, time spent with the patient and family by the criticare teams during their routine ICU care.
Read more such content on Hidoc Dr | Medical Learning App for Doctors
1.
Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT
2.
Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer
3.
Resection for Early Liver Cancer Tied to Improved Survival.
4.
Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients
5.
Prior authorizations draining time, energy from many cancer patients
1.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
2.
AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency
3.
Understanding Axitinib: What You Need To Know For Your Treatment Plan
4.
Understanding Extramammary Paget's Disease: Causes, Symptoms and Treatment Options
5.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Understanding the causes of anemia in adults beyond nutritional deficiencies
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
3.
Navigating the Complexities of Ph Negative ALL - Part V
4.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation